A Phase 3, Randomized, Double-Blind, Placebo-Controlled,

Project: Research project

Project Details

Description

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Evaluating the Efficacy and Safety of IPI-504 in Patients with Metastatic and/or Unresectable Gastrointestinal Stromal Tumors Following Failure of at Least Imatinib and Sunitinib
StatusFinished
Effective start/end date5/5/0812/31/12

Funding

  • INFINITY PHARMACEUTICALS, INC